CEO Kevin Ali Marks Organon’s Progress In First Post-Spin Year

Women’s Health Build-Up Continues Through Deals

A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.

Three white checkmarks on multicolored toy circles in a row in the middle on bright aqua blue background
Ali highlighted progress across all three Organon businesses – established brands, biosimilars and women's health • Source: Shutterstock

Organon & Co. CEO Kevin Ali is the first to admit that the company faced a lot of skepticism when it spun out of Merck & Co., Inc. with three seemingly disparate sets of assets – established products, biosimilars and women’s health – with plans to most aggressively invest in women’s health for growth. Ali is also the first to note that the company has delivered on its promises across all three areas during its first year.

“Investors and analysts at the very beginning when we first spun out were wondering how these three pieces of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By 

Series B cash will be used to advance its Stargardt disease gene therapy.

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By 

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By 

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By 

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

More from Business

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By 

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

 
• By 

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.